Recent clinical trials surrounding the medication Retatrutide , specifically the 120mg formulation referred to as ZPHC, reveal a considerable benefit on body mass loss and associated chronic conditions . Researchers believe that this dual agonist , targeting both GLP-1 and GIP pathways , could provide a major improvement in the management of overwe